254000000 shares in issue
0.9% 2nd Nov £1.10 228600 £251460
.12% 20 Aug £1.13 304800 £344424
.11% 12 August £1.18 279400 £329692
.52% 2nd July £1.31 1320800 £1730248
Total Shares Short 2113600
Cost £2655824
Average paid £1.2565
Juniper are now already underwater, their average price on the short was about 1.2565 because they kept shorting as the SP kept rising. For every 5p on the SP, they're £105k down. Let's see what tomorrow brings but any news and it could get very ugly for them.
Got the calculator out earlier and because Jupiter continued to add to their short in Aug and Nov, their average is only £1.2565 so if today's action continues over the next few days they'll be hitting the panic button fairly soon. Should be an interesting few days ahead......
Use the Way back Machine to check older versions of the website
https://web.archive.org/web/20210101000000*/avacta.com
You can go back as far as 2004
Synairgen is just a small bio tech that's having multiple conversations with multiple drug regulators, governments and large pharma across the USA, UK and the EU plus have multiple trials running. They're flat out busy trying to get SNG001 approved and into peoples lungs.....
I'm so comfortable with this investment.
I couldn't disagree more, this board are definitely not useless. It was a restatement of what is going on, they're 100% focused on getting this drug to market worldwide and extending its use to treat other respiratory illnesses. They've so many positive things going on, just needs shareholders to be patient. Activ2 news could drop anytime and India/South America will drive P3 numbers very quickly. They could also drop long Covid news fairly shortly.
Buy and Hold, sit on your hands.
Ditto Rix, exactly the same happened to me back in early March but I had symptoms, took both an Innova LFT and a PCR test within 10 mins of each other. My wife is a nurse so I know the LFT test was done correctly. Came back negative but the PCR was positive (which I expected). I think the Innova tests have been very dangerous for the UK and have caused many deaths. Can't wait for the UK to be totally rid of them.
Doxorubicin is a very effective drug but it's market is limited due to toxicity which AS mentioned. It's why Avacta has focused on it. With Avacta resolving the the toxicity issue, the Dox market would increase rapidly overnight but also prove the value in the pre CISION platform.
Yes still on ACTIV-2 but they'll be watching it very closely.
The NIAID-supported ACTIV-2 trial will continue to test the BRII-196 and BRII-198 combination monoclonal antibody therapeutic regimen in people with mild-to-moderate COVID-19 who have not required hospitalization. It is being overseen by the same DSMB that oversees ACTIV-3, and the DSMB does not recommend any changes to ACTIV-2 at this time.